Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Chugai Pharmaceutical Co Ltd    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO LTD (4519)
My previous session
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Chugai Pharmaceutical Co., Ltd. - Galderma Announces the Results of Phase 2b Study of Nemolizumab in Patients with Atopic Dermatitis

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/01/2018 | 04:13pm CET

TOKYO - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Galderma, Nestle Skin Health's Medical Solutions Business issued a press release regarding the results of phase 2b study of nemolizumab (CIM331) created by Chugai in patients with moderate-to-severe atopic dermatitis to investigate the efficacy and safety of nemolizumab.

Please refer to the link below for details of the press release: Galderma Announces Positive Results from Phase 2b Study of Nemolizumab in Patients with Moderate-to-Severe Atopic Dermatitis

https://www.nestleskinhealth.com/news/galderma-announces-positive-results-phase-2b-study-nemolizumab-patients-moderate-severe-atopic

Contact:

Tomoko Shimizu

Tel: +81-3-3273-0881

Email: pr@chugai-pharm.co.jp

(C) 2018 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CHUGAI PHARMACEUTICAL CO LTD -0.29% 6870 End-of-day quote.19.06%
NESTLÉ 0.05% 84.96 Delayed Quote.1.34%
ROCHE HOLDING -0.72% 249.6 Delayed Quote.2.11%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CHUGAI PHARMACEUTICAL CO L
11/01Chugai Pharmaceutical Co., Ltd. - Galderma Announces the Results of Phase 2b ..
AQ
11/01Chugai Pharmaceutical Co., Ltd. - Withdrawal of Lawsuits and Petitions for Pr..
AQ
10/19Chugai Pharmaceutical Co., Ltd. - Xeloda Adherence Support App Contributes to..
AQ
10/19CHUGAI PHARMACEUTICAL : A First Approach in the Pharmaceutical Industry Starting..
AQ
10/18ROCHE : Chugai - F. Hoffmann-La Roche Announces Third Quarter Sales 2018
AQ
10/17CHUGAI PHARMACEUTICAL : Presents Results from Phase III Study of Satralizumab in..
AQ
10/17CHUGAI PHARMACEUTICAL : Expresses its Support for the 'Japan Climate Action Summ..
AQ
10/15CHUGAI PHARMACEUTICAL : Presents Results from Phase III Study of Satralizumab in..
BU
10/12CHUGAI PHARMACEUTICAL : Releases Disease Awareness Anime about Rheumatoid Arthri..
BU
10/10CHUGAI PHARMACEUTICAL : HEMLIBRA Receives Regulatory Approval from U.S. FDA for ..
AQ
More news
News from SeekingAlpha
10/15Chugai's satralizumab shows positive effect in late-stage study in inflammato.. 
07/27Chugai Pharmaceutical Co., Ltd. ADR 2018 Q2 - Results - Earnings Call Slides 
05/31ALEXION PHARMACEUTICALS : Clinical Progress, Acquisitions And The Competition (P.. 
04/27Chugai Pharmaceutical's (CHGCF) Management on Q1 2018 Results - Earnings Call.. 
04/25Chugai Pharmaceutical Co., Ltd. ADR 2018 Q1 - Results - Earnings Call Slides 
Financials (JPY)
Sales 2018 564 B
EBIT 2018 112 B
Net income 2018 88 689 M
Finance 2018 216 B
Yield 2018 1,01%
P/E ratio 2018 42,24
P/E ratio 2019 33,79
EV / Sales 2018 6,43x
EV / Sales 2019 5,81x
Capitalization 3 845 B
Chart CHUGAI PHARMACEUTICAL CO LTD
Duration : Period :
Chugai Pharmaceutical Co Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO L
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Average target price 6 254  JPY
Spread / Average Target -9,0%
EPS Revisions
Managers
NameTitle
Tatsuro Kosaka President, CEO & Representative Director
Osamu Nagayama Chairman
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Hisanori Takanashi Manager-R&D Portfolio Management Department
Sector and Competitors
1st jan.Capitalization (M$)
CHUGAI PHARMACEUTICAL CO LTD19.06%33 748
--.--%0
--.--%0